ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

6.26%

$5.60

Market Cap $86.68M

Healthcare Medical Devices

Anteris Technologies Global Corp. is a structural heart company, which is engaged in... Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

AVR	Appendix 4E & 31 December 2017 Financial Report	PRICE SENSITIVE	28/02/18	795.64KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/18	691KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/18	632.92KB	Share
AVR	Regulatory approval to launch CardioCel in India	PRICE SENSITIVE	22/11/17	272.93KB	Share
AVR	Update on Admedus shaped patch product franchise	PRICE SENSITIVE	14/11/17	286.79KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/17	210.45KB	Share
AVR	Admedus announces facility agreement with PFG	PRICE SENSITIVE	26/10/17	368.25KB	Share
AVR	Trading Halt	PRICE SENSITIVE	24/10/17	285.57KB	Share
AVR	Admedus TAVR project on track with new IP application	PRICE SENSITIVE	24/10/17	269.42KB	Share
AVR	Notice of Annual General Meeting	PRICE SENSITIVE	13/10/17	276.01KB	Share
AVR	Exclusive Supply Agreement with 4C Medical	PRICE SENSITIVE	31/08/17	122.12KB	Share
AVR	FY17 Full Year Results Announcement	PRICE SENSITIVE	31/08/17	593KB	Share
AVR	Appendix 4E & Preliminary Final Report	PRICE SENSITIVE	31/08/17	660.5KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	26/07/17	603.1KB	Share
AVR	Update on the CardioCel 3D Product Launch	PRICE SENSITIVE	07/07/17	144.38KB	Share
AVR	Response to Aware Query	PRICE SENSITIVE	09/05/17	461.4KB	Share
AVR	Admedus Releases Results of HSV-2 Phase IIa Study	PRICE SENSITIVE	04/05/17	745.14KB	Share
AVR	Admedus Receives FDA Clearance for CardioCel 3D	PRICE SENSITIVE	02/05/17	516.73KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	26/04/17	565.14KB	Share
AVR	Admedus Appoints Wayne Paterson as CEO	PRICE SENSITIVE	15/03/17	414.5KB	Share
AVR	S&P DJ Indices Announces March Quarterly Rebalance	PRICE SENSITIVE	10/03/17	177.37KB	Share
AVR	Approval and first sales in Saudi Arabia	PRICE SENSITIVE	28/02/17	441.35KB	Share
AVR	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/17	741.98KB	Share
AVR	Admedus Announces Half Yearly Report	PRICE SENSITIVE	24/02/17	626.68KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/17	470.71KB	Share
AVR	Admedus Finishes 2016 with Growing Revenue	PRICE SENSITIVE	23/12/16	474.61KB	Share
AVR	CardioCel receives market approval in UAE	PRICE SENSITIVE	21/11/16	462.53KB	Share
AVR	Appendix 4C - quarterly-AHZ.AX	PRICE SENSITIVE	28/10/16	447.24KB	Share
AVR	HSV-2 Interim Results Announcement-AHZ.AX	PRICE SENSITIVE	19/10/16	437.24KB	Share
AVR	FDA Clearance Granted for VascuCel-AHZ.AX	PRICE SENSITIVE	17/10/16	421.85KB	Share
AVR	Admedus Strengthens Management Team-AHZ.AX	PRICE SENSITIVE	26/09/16	423.38KB	Share
AVR	Settlement of Federal Court Proceedings-AHZ.AX	PRICE SENSITIVE	09/09/16	360.84KB	Share
AVR	Admedus Successfully Completes $8.3M Rights Issue-AHZ.AX	PRICE SENSITIVE	01/09/16	423.24KB	Share
AVR	Annual Report to shareholders and Appendix 4E-AHZ.AX	PRICE SENSITIVE	31/08/16	1.67MB	Share
AVR	Letter to Shareholders-AHZ.AX	PRICE SENSITIVE	28/08/16	362.62KB	Share
AVR	Letter to Shareholders-AHZ.AX	PRICE SENSITIVE	25/08/16	362.62KB	Share
AVR	Prospectus - Entitlement Offer-AHZ.AX	PRICE SENSITIVE	02/08/16	2.66MB	Share
AVR	Capital Raise Announcement-AHZ.AX	PRICE SENSITIVE	29/07/16	395.31KB	Share
AVR	Trading Halt-AHZ.AX	PRICE SENSITIVE	27/07/16	238.01KB	Share
AVR	Appendix 4C - quarterly-AHZ.AX	PRICE SENSITIVE	20/07/16	455.72KB	Share
AVR	Admedus Investor Webinar-AHZ.AX	PRICE SENSITIVE	11/07/16	1.34MB	Share
AVR	Trading Halt-AHZ.AX	PRICE SENSITIVE	11/07/16	625.6KB	Share
AVR	Admedus Awared Major Supply Tender-AHZ.AX	PRICE SENSITIVE	25/05/16	420.38KB	Share
AVR	Managing Director Resignation-AHZ.AX	PRICE SENSITIVE	23/05/16	402.53KB	Share
AVR	Appendix 4C - quarterly-AHZ.AX	PRICE SENSITIVE	29/04/16	414.25KB	Share
AVR	CORONEO Australia New Zealand Distribution Partnership-AHZ.AX	PRICE SENSITIVE	08/04/16	426.35KB	Share
AVR	HSV-2 Phase II Initial Results	PRICE SENSITIVE	04/03/16	379.27KB	Share
AVR	Half Yearly Report	PRICE SENSITIVE	26/02/16	1.14MB	Share
AVR	HSV-2 Study timelines update	PRICE SENSITIVE	15/02/16	426.82KB	Share
AVR	Admedus First MENA Sales	PRICE SENSITIVE	03/02/16	422.4KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	28/01/16	470.92KB	Share
AVR	Admedus signs exclusive distribution agreement with CORONEO	PRICE SENSITIVE	27/01/16	428.42KB	Share
AVR	Admedus End of Year Update	PRICE SENSITIVE	24/12/15	427.43KB	Share
AVR	Admedus announces US$5M Placement of shares	PRICE SENSITIVE	22/12/15	237.23KB	Share
AVR	Trading Halt	PRICE SENSITIVE	18/12/15	423KB	Share
AVR	Admedus achieves label expansion for CardioCel in Europe	PRICE SENSITIVE	09/11/15	213.85KB	Share
AVR	Admedus first sales in Malaysia	PRICE SENSITIVE	04/11/15	213.62KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/10/15	439.2KB	Share
AVR	Positive CardioCel valve reconstruction data	PRICE SENSITIVE	06/10/15	312.86KB	Share
AVR	Admedus initiates collaboration on stem cell delivery	PRICE SENSITIVE	30/09/15	312.03KB	Share
AVR	Admedus initiates heart valve clinical study	PRICE SENSITIVE	23/09/15	283.38KB	Share
AVR	Amedus Expands CardioCel Portfolio to Meet Surgical Needs	PRICE SENSITIVE	03/09/15	309.93KB	Share
AVR	Annual Report to shareholders and Appendix 4E	PRICE SENSITIVE	27/08/15	346.86KB	Share
AVR	Admedus HSV-2 Phase II Study Interim Update	PRICE SENSITIVE	27/08/15	315.35KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/15	353.16KB	Share
AVR	CardioCel shows no evidence of calcification after 7 years	PRICE SENSITIVE	08/07/15	339.18KB	Share
AVR	CardioCel approval in Singapore	PRICE SENSITIVE	18/06/15	420.95KB	Share
AVR	Admedus HSV-2 Phase II Update	PRICE SENSITIVE	05/06/15	283.61KB	Share
AVR	New CardioCel product for vascular repair	PRICE SENSITIVE	18/05/15	277.75KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/04/15	367.14KB	Share
AVR	Admedus appoints Genpharm as CardioCel distributor in MENA	PRICE SENSITIVE	22/04/15	318.77KB	Share
AVR	Admedus Herpes Phase II - First dosing to commence	PRICE SENSITIVE	10/04/15	284.02KB	Share
AVR	Admedus expands market for ADAPT tissue products	PRICE SENSITIVE	07/04/15	280.41KB	Share
AVR	Non-Renounceable Right Issue Offer Document	PRICE SENSITIVE	30/03/15	279.86KB	Share
AVR	Non-Renounceable Right Issue Offer Document	PRICE SENSITIVE	20/03/15	561.15KB	Share
AVR	Admedus announces Placement and Rights Issue	PRICE SENSITIVE	18/03/15	290.29KB	Share
AVR	Trading Halt	PRICE SENSITIVE	16/03/15	362.09KB	Share
AVR	Admedus expands CardioCel market	PRICE SENSITIVE	12/03/15	277.83KB	Share
AVR	Half Year Report	PRICE SENSITIVE	27/02/15	225.86KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/01/15	387.46KB	Share
AVR	Admedus End of Year Update	PRICE SENSITIVE	24/12/14	289.38KB	Share
AVR	HPV Vaccine Heads to the Clinic	PRICE SENSITIVE	24/11/14	299.01KB	Share
AVR	CardioCel gains special access in Singapore	PRICE SENSITIVE	03/11/14	339.88KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/10/14	289.96KB	Share
AVR	CardioCel granted Medical Device Licence in Canada	PRICE SENSITIVE	20/10/14	291.33KB	Share
AVR	Admedus announces further data from HSV-2 Trial	PRICE SENSITIVE	02/10/14	427.97KB	Share
AVR	Annual Report to shareholders and Appendix 4E	PRICE SENSITIVE	28/08/14	1.53MB	Share
AVR	Admedus ships CardioCel to US from new facility	PRICE SENSITIVE	14/08/14	322.99KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	30/07/14	291.14KB	Share
AVR	Admedus increases holding in Admedus Vaccines	PRICE SENSITIVE	24/07/14	342.65KB	Share
AVR	Admedus End of Financial Year Update	PRICE SENSITIVE	26/06/14	353.61KB	Share
AVR	Admedus announces Placement and SPP	PRICE SENSITIVE	12/05/14	341.69KB	Share
AVR	Trading Halt	PRICE SENSITIVE	08/05/14	354.98KB	Share
AVR	CardioCel Sales Update - First sales order for the US	PRICE SENSITIVE	07/05/14	280.17KB	Share
AVR	CardioCel 6 year data shows no calcification	PRICE SENSITIVE	01/05/14	277.68KB	Share
AVR	AHZ 4C March 2014 quarter	PRICE SENSITIVE	24/04/14	407.37KB	Share
AVR	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/14	149.83KB	Share
AVR	Admedus's CardioCel Cleared for Sale in the US	PRICE SENSITIVE	10/02/14	279.96KB	Share
AVR	Admedus Herpes Interim Phase I Results	PRICE SENSITIVE	03/02/14	277.59KB	Share
AVR	Appendix 4C - quarterly	PRICE SENSITIVE	31/01/14	412.6KB	Share

AVR Appendix 4E & 31 December 2017 Financial Report
28/02/18	PRICE SENSITIVE	795.64KB	Share
AVR Appendix 4C - quarterly
31/01/18	PRICE SENSITIVE	691KB	Share
AVR Appendix 4C - quarterly
30/01/18	PRICE SENSITIVE	632.92KB	Share
AVR Regulatory approval to launch CardioCel in India
22/11/17	PRICE SENSITIVE	272.93KB	Share
AVR Update on Admedus shaped patch product franchise
14/11/17	PRICE SENSITIVE	286.79KB	Share
AVR Appendix 4C - quarterly
31/10/17	PRICE SENSITIVE	210.45KB	Share
AVR Admedus announces facility agreement with PFG
26/10/17	PRICE SENSITIVE	368.25KB	Share
AVR Trading Halt
24/10/17	PRICE SENSITIVE	285.57KB	Share
AVR Admedus TAVR project on track with new IP application
24/10/17	PRICE SENSITIVE	269.42KB	Share
AVR Notice of Annual General Meeting
13/10/17	PRICE SENSITIVE	276.01KB	Share
AVR Exclusive Supply Agreement with 4C Medical
31/08/17	PRICE SENSITIVE	122.12KB	Share
AVR FY17 Full Year Results Announcement
31/08/17	PRICE SENSITIVE	593KB	Share
AVR Appendix 4E & Preliminary Final Report
31/08/17	PRICE SENSITIVE	660.5KB	Share
AVR Appendix 4C - quarterly
26/07/17	PRICE SENSITIVE	603.1KB	Share
AVR Update on the CardioCel 3D Product Launch
07/07/17	PRICE SENSITIVE	144.38KB	Share
AVR Response to Aware Query
09/05/17	PRICE SENSITIVE	461.4KB	Share
AVR Admedus Releases Results of HSV-2 Phase IIa Study
04/05/17	PRICE SENSITIVE	745.14KB	Share
AVR Admedus Receives FDA Clearance for CardioCel 3D
02/05/17	PRICE SENSITIVE	516.73KB	Share
AVR Appendix 4C - quarterly
26/04/17	PRICE SENSITIVE	565.14KB	Share
AVR Admedus Appoints Wayne Paterson as CEO
15/03/17	PRICE SENSITIVE	414.5KB	Share
AVR S&P DJ Indices Announces March Quarterly Rebalance
10/03/17	PRICE SENSITIVE	177.37KB	Share
AVR Approval and first sales in Saudi Arabia
28/02/17	PRICE SENSITIVE	441.35KB	Share
AVR Half Yearly Report and Accounts
24/02/17	PRICE SENSITIVE	741.98KB	Share
AVR Admedus Announces Half Yearly Report
24/02/17	PRICE SENSITIVE	626.68KB	Share
AVR Appendix 4C - quarterly
31/01/17	PRICE SENSITIVE	470.71KB	Share
AVR Admedus Finishes 2016 with Growing Revenue
23/12/16	PRICE SENSITIVE	474.61KB	Share
AVR CardioCel receives market approval in UAE
21/11/16	PRICE SENSITIVE	462.53KB	Share
AVR Appendix 4C - quarterly-AHZ.AX
28/10/16	PRICE SENSITIVE	447.24KB	Share
AVR HSV-2 Interim Results Announcement-AHZ.AX
19/10/16	PRICE SENSITIVE	437.24KB	Share
AVR FDA Clearance Granted for VascuCel-AHZ.AX
17/10/16	PRICE SENSITIVE	421.85KB	Share
AVR Admedus Strengthens Management Team-AHZ.AX
26/09/16	PRICE SENSITIVE	423.38KB	Share
AVR Settlement of Federal Court Proceedings-AHZ.AX
09/09/16	PRICE SENSITIVE	360.84KB	Share
AVR Admedus Successfully Completes $8.3M Rights Issue-AHZ.AX
01/09/16	PRICE SENSITIVE	423.24KB	Share
AVR Annual Report to shareholders and Appendix 4E-AHZ.AX
31/08/16	PRICE SENSITIVE	1.67MB	Share
AVR Letter to Shareholders-AHZ.AX
28/08/16	PRICE SENSITIVE	362.62KB	Share
AVR Letter to Shareholders-AHZ.AX
25/08/16	PRICE SENSITIVE	362.62KB	Share
AVR Prospectus - Entitlement Offer-AHZ.AX
02/08/16	PRICE SENSITIVE	2.66MB	Share
AVR Capital Raise Announcement-AHZ.AX
29/07/16	PRICE SENSITIVE	395.31KB	Share
AVR Trading Halt-AHZ.AX
27/07/16	PRICE SENSITIVE	238.01KB	Share
AVR Appendix 4C - quarterly-AHZ.AX
20/07/16	PRICE SENSITIVE	455.72KB	Share
AVR Admedus Investor Webinar-AHZ.AX
11/07/16	PRICE SENSITIVE	1.34MB	Share
AVR Trading Halt-AHZ.AX
11/07/16	PRICE SENSITIVE	625.6KB	Share
AVR Admedus Awared Major Supply Tender-AHZ.AX
25/05/16	PRICE SENSITIVE	420.38KB	Share
AVR Managing Director Resignation-AHZ.AX
23/05/16	PRICE SENSITIVE	402.53KB	Share
AVR Appendix 4C - quarterly-AHZ.AX
29/04/16	PRICE SENSITIVE	414.25KB	Share
AVR CORONEO Australia New Zealand Distribution Partnership-AHZ.AX
08/04/16	PRICE SENSITIVE	426.35KB	Share
AVR HSV-2 Phase II Initial Results
04/03/16	PRICE SENSITIVE	379.27KB	Share
AVR Half Yearly Report
26/02/16	PRICE SENSITIVE	1.14MB	Share
AVR HSV-2 Study timelines update
15/02/16	PRICE SENSITIVE	426.82KB	Share
AVR Admedus First MENA Sales
03/02/16	PRICE SENSITIVE	422.4KB	Share
AVR Appendix 4C - quarterly
28/01/16	PRICE SENSITIVE	470.92KB	Share
AVR Admedus signs exclusive distribution agreement with CORONEO
27/01/16	PRICE SENSITIVE	428.42KB	Share
AVR Admedus End of Year Update
24/12/15	PRICE SENSITIVE	427.43KB	Share
AVR Admedus announces US$5M Placement of shares
22/12/15	PRICE SENSITIVE	237.23KB	Share
AVR Trading Halt
18/12/15	PRICE SENSITIVE	423KB	Share
AVR Admedus achieves label expansion for CardioCel in Europe
09/11/15	PRICE SENSITIVE	213.85KB	Share
AVR Admedus first sales in Malaysia
04/11/15	PRICE SENSITIVE	213.62KB	Share
AVR Appendix 4C - quarterly
30/10/15	PRICE SENSITIVE	439.2KB	Share
AVR Positive CardioCel valve reconstruction data
06/10/15	PRICE SENSITIVE	312.86KB	Share
AVR Admedus initiates collaboration on stem cell delivery
30/09/15	PRICE SENSITIVE	312.03KB	Share
AVR Admedus initiates heart valve clinical study
23/09/15	PRICE SENSITIVE	283.38KB	Share
AVR Amedus Expands CardioCel Portfolio to Meet Surgical Needs
03/09/15	PRICE SENSITIVE	309.93KB	Share
AVR Annual Report to shareholders and Appendix 4E
27/08/15	PRICE SENSITIVE	346.86KB	Share
AVR Admedus HSV-2 Phase II Study Interim Update
27/08/15	PRICE SENSITIVE	315.35KB	Share
AVR Appendix 4C - quarterly
30/07/15	PRICE SENSITIVE	353.16KB	Share
AVR CardioCel shows no evidence of calcification after 7 years
08/07/15	PRICE SENSITIVE	339.18KB	Share
AVR CardioCel approval in Singapore
18/06/15	PRICE SENSITIVE	420.95KB	Share
AVR Admedus HSV-2 Phase II Update
05/06/15	PRICE SENSITIVE	283.61KB	Share
AVR New CardioCel product for vascular repair
18/05/15	PRICE SENSITIVE	277.75KB	Share
AVR Appendix 4C - quarterly
30/04/15	PRICE SENSITIVE	367.14KB	Share
AVR Admedus appoints Genpharm as CardioCel distributor in MENA
22/04/15	PRICE SENSITIVE	318.77KB	Share
AVR Admedus Herpes Phase II - First dosing to commence
10/04/15	PRICE SENSITIVE	284.02KB	Share
AVR Admedus expands market for ADAPT tissue products
07/04/15	PRICE SENSITIVE	280.41KB	Share
AVR Non-Renounceable Right Issue Offer Document
30/03/15	PRICE SENSITIVE	279.86KB	Share
AVR Non-Renounceable Right Issue Offer Document
20/03/15	PRICE SENSITIVE	561.15KB	Share
AVR Admedus announces Placement and Rights Issue
18/03/15	PRICE SENSITIVE	290.29KB	Share
AVR Trading Halt
16/03/15	PRICE SENSITIVE	362.09KB	Share
AVR Admedus expands CardioCel market
12/03/15	PRICE SENSITIVE	277.83KB	Share
AVR Half Year Report
27/02/15	PRICE SENSITIVE	225.86KB	Share
AVR Appendix 4C - quarterly
30/01/15	PRICE SENSITIVE	387.46KB	Share
AVR Admedus End of Year Update
24/12/14	PRICE SENSITIVE	289.38KB	Share
AVR HPV Vaccine Heads to the Clinic
24/11/14	PRICE SENSITIVE	299.01KB	Share
AVR CardioCel gains special access in Singapore
03/11/14	PRICE SENSITIVE	339.88KB	Share
AVR Appendix 4C - quarterly
31/10/14	PRICE SENSITIVE	289.96KB	Share
AVR CardioCel granted Medical Device Licence in Canada
20/10/14	PRICE SENSITIVE	291.33KB	Share
AVR Admedus announces further data from HSV-2 Trial
02/10/14	PRICE SENSITIVE	427.97KB	Share
AVR Annual Report to shareholders and Appendix 4E
28/08/14	PRICE SENSITIVE	1.53MB	Share
AVR Admedus ships CardioCel to US from new facility
14/08/14	PRICE SENSITIVE	322.99KB	Share
AVR Appendix 4C - quarterly
30/07/14	PRICE SENSITIVE	291.14KB	Share
AVR Admedus increases holding in Admedus Vaccines
24/07/14	PRICE SENSITIVE	342.65KB	Share
AVR Admedus End of Financial Year Update
26/06/14	PRICE SENSITIVE	353.61KB	Share
AVR Admedus announces Placement and SPP
12/05/14	PRICE SENSITIVE	341.69KB	Share
AVR Trading Halt
08/05/14	PRICE SENSITIVE	354.98KB	Share
AVR CardioCel Sales Update - First sales order for the US
07/05/14	PRICE SENSITIVE	280.17KB	Share
AVR CardioCel 6 year data shows no calcification
01/05/14	PRICE SENSITIVE	277.68KB	Share
AVR AHZ 4C March 2014 quarter
24/04/14	PRICE SENSITIVE	407.37KB	Share
AVR Half Yearly Report and Accounts
26/02/14	PRICE SENSITIVE	149.83KB	Share
AVR Admedus's CardioCel Cleared for Sale in the US
10/02/14	PRICE SENSITIVE	279.96KB	Share
AVR Admedus Herpes Interim Phase I Results
03/02/14	PRICE SENSITIVE	277.59KB	Share
AVR Appendix 4C - quarterly
31/01/14	PRICE SENSITIVE	412.6KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $5.60		Change 0.330(6.26%)		Mkt cap ! $86.68M

Open	High	Low	Value	Volume
$5.50	$5.60	$5.30	$89.45K	16.14K

Buyers (Bids)

No.	Vol.	Price($)
1	103	$5.30

Sellers (Offers)

Price($)	Vol.	No.
$5.98	992	1

View Market Depth

No.	Vol.	Price($)
1	103	5.300
1	920	5.270
1	613	5.240
1	576	5.200
1	20000	5.150

Price($)	Vol.	No.
5.980	992	1
5.990	3500	1
6.000	3719	2
6.050	20000	1
6.500	230	2

Last trade - 15.29pm 22/08/2025 (20 minute delay)


Last $5.59		Change 0.330 ( 4.68 %)
Open	High	Low	Volume
$5.59	$5.59	$5.29	3526
Last updated 15.28pm 22/08/2025 ?

AVR (ASX) Chart

ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

EV Resources executes strategic MOU with Wogen, XCLR to fund and advance Los Lirios antimony project

Top Stories

ANTERIS TECHNOLOGIES GLOBAL CORP. - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

EV Resources executes strategic MOU with Wogen, XCLR to fund and advance Los Lirios antimony project

Top Stories

Corporate Spotlight
Not Yet Available